More / Better Life?

Humanity extended life spectacularly, from Semmelweis to plummeting infant mortality to the post-50 health revolution, without ever calling it "longevity science." The label arrived later, and with it a blurring of terms: average lifespan, maximum lifespan, and healthspan (the years lived in good health) are not the same thing, and only one of them is what most people actually want more of. Nor are the gains we take for granted secure: AMR threatens a post-antibiotic era, climate change is driving organ damage and infectious diseases toward the poles, and the interventions with the strongest evidence (food, movement, social connection) are the ones the longevity industry talks about least. Nordics+, with the world’s oldest populations, richest health registries, and strongest prevention cultures, sits at the center of this tension, and the choices it makes on data infrastructure, market access, manufacturing, and ethical boundaries will determine whether the region leads or merely ages. This session establishes the day's scientific and human framework.

Assessing whether longevity interventions actually work requires tracking populations for decades, and measuring healthspan, not just survival. The Nordics+ should be the global leader here: interconnected registries, digitally native populations and universal healthcare together form one of the world's richest engines for medical discovery. Yet the advantage is underused. Each country builds its own platforms and guards its own data, cross-border research remains rare, and when it is attempted the registries often fail to line up. Industry reports that access delays are its primary competitive challenge, and that it avoids cross-border studies as a result. Underneath sits a harder question about control: who may reach this data, who captures the value of what runs through it, and who can keep it safe. Can the Nordics+ make its data interoperable enough to generate transformative research, workable enough to reward the companies that use it, and resilient enough to protect what has become a strategic asset? 

Do the most powerful interventions live at the intersection of molecules and discipline? Could structured cognitive or sensory training amplify a drug's effect, or pairing pharmacology with brain exercise slow decline in ways neither achieves alone? The science is promising but unproven, and this is where the region holds a distinctive advantage: Israel's pioneering work in brain, cognition, and technology offers the neuroscience, while the Nordics+ tradition of treating movement and lifestyle as medicine offers the means to test whether synergy is real or wishful thinking. How would a single-payer system reimburse a therapy that is part pill, part protocol? Can Nordics+ and its partners pioneer the disciplined study of combination approaches that industry alone cannot validate?

The longevity industry promises more life at any cost. The Nordic tradition whispers lagom (enough is enough) and asks whether the measure that matters is healthspan rather than years alone. But which instinct should guide a region that has both the scientific firepower to push boundaries and the egalitarian values to ask whether it should? Novo Nordisk is Danish, yet GLP-1 access varies across the Nordics+. The welfare model promised universal, equal care: what happens when 30% of the population is over 65 and the most promising interventions are priced for the few? Should Nordics+ pursue longevity science aggressively and sort out access later, or is restraint itself a form of leadership? Can wisdom and ambition coexist, or does a region that optimizes for healthspan forfeit the frontier? 

The next generation of longevity technologies is arriving now. The Nordics+ has the scientific firepower to lead, but the binding constraint is capital. Often, breakthroughs discovered in Nordic labs scale in Boston, because the risk capital, late-stage financing, and appetite for long bets live elsewhere. The region faces a choice: build the platform and risk being undercapitalized, or license it away and capture only a fraction of the value. Value licensed abroad is value not reinvested in the region's own health system, and its patients end up waiting for therapies developed elsewhere and priced for other markets, in a region where the over-65 population has grown by nearly a third in 25 years while the working-age population has shrunk, and where the supply chain beneath even the medicines it does make runs through a handful of countries far away. Which platforms are ready to build on, and which are still more promise than proof? Where should the region commit capital to lead rather than license? And can Nordics+ capture the value of its own science before the window closes?